Form 4: Heron Therapeutics Director Craig Johnson Acquires Stock and Options

Director Craig Johnson of Heron Therapeutics acquired 17,950 restricted stock units and 35,900 stock options on January 30, 2025.

Summary

• Craig Johnson, a director at Heron Therapeutics, acquired 17,950 restricted stock units and 35,900 stock options on January 30, 2025.
• The restricted stock units vest fully on January 30, 2026, and each unit represents the right to receive one share of common stock.
• The stock options vest in 12 equal monthly installments starting one month after the grant date and expire on January 30, 2035.
• The exercise price for the stock options is $1.73 per share.
• Following these transactions, Mr. Johnson beneficially owns 83,770 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it shows alignment of interests between management and shareholders. The sentiment is neutral to slightly positive.

Positives

• The acquisition of stock and options by a director may signal confidence in the company's future prospects.
• The vesting schedule of the stock options and restricted stock units aligns the director's interests with the long-term performance of the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• The vesting schedule for the restricted stock units and stock options is typical for executive compensation packages in the biotechnology industry.
• The exercise price of $1.73 for the stock options is a common practice, often set at or near the market price at the time of grant.
• Similar filings are made by directors and officers of other publicly traded companies such as Amgen, Gilead, and Regeneron when they receive or transact in company stock.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment as it indicates a director's confidence in the company.

Key Dates

Keywords

Heron Therapeutics, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Equity, HRTX